Mark Hopman, Chief Commercial Officer at Beta Bionics, Inc. (BBNX), sold 775 shares at $15.52 ($12K) on 2026-09-14, disclosed to the SEC on 2026-09-15.
Scheduled sale ($12k) by Chief Commercial Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| BBNX | SELL | 2026-09-18 | $665K | — | Filing → |
| BBNX | SELL | 2026-09-17 | $620K | — | Filing → |
| BBNX | SELL | 2026-09-10 | $681K | — | Filing → |